Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.1
4.7
Journals
Viruses
Special Issues
Simian Immunodeficiency Virus Models of HIV/AIDS in Nonhuman Primates 2024
share announcement

Simian Immunodeficiency Virus Models of HIV/AIDS in Nonhuman Primates 2024

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "General Virology".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 4907

Special Issue Editors

Dr. Cynthia Derdeyn

E-Mail Website
Guest Editor
1. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA
2. Infectious Diseases and Translational Medicine Unit, Washington National Primate Research Center, Seattle, WA, USA
Interests: HIV-1; B cells; neutralizing antibodies; SIV; vaccines
Dr. Donald Sodora

E-Mail Website
Guest Editor
Seattle Children's Research Institute, Seattle, WA, USA
Interests: HIV-1 transmission; AIDS; developing new therapies and vaccines
Dr. Jennifer A. Manuzak

E-Mail Website
Guest Editor
1. Division of Immunology, Tulane National Primate Research Center, Covington, LA, USA
2. Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA
Interests: HIV; SIV; co-infections; mucosal immunity; innate immunity
Dr. Nina Derby

E-Mail Website
Guest Editor
Seattle Children's Research Institute, Seattle, WA, USA
Interests: HIV-1; SIV liver disease; innate immunity herpes simplex virus

Special Issue Information

Dear Colleagues,

Human immunodeficiency virus type 1 (HIV-1) is the causative agent of the ongoing AIDS pandemic. HIV-1 infection is a life-long infection associated with high mortality. Currently, it is estimated that 38 million people live with HIV/AIDS worldwide, causing devastating socioeconomic consequences. Antiretroviral treatment combinations exist for viral suppression and prophylaxis, but their efficacy can be decreased by toxicity, limited access, and viral resistance. Moreover, no protective vaccination or virus eradication strategies exist. Addressing these shortcomings requires the strategic use of animal models that recapitulate the key features of HIV/AIDS, including transmission, immune responses, viral reservoirs, and pathogenesis. HIV/AIDS also occurs in the context of other globally significant human diseases, including tuberculosis and malaria, necessitating the development of robust models to dissect the complex interplay of immunopathologies. To this end, nonhuman primate models have been established using simian immunodeficiency virus (SIV) variants that exhibit clinical, immunologic, virologic, and pathogenic sequelae similar to HIV/AIDS. These models have been used extensively for studies of pathogenesis, prevention, and cures, as well as co-infections. In addition, SIV variants can cause viremic but non-pathogenic infections when replicating in their natural host species, giving an insight into how the progression to AIDS could be prolonged or avoided. Finally, for studies that target the HIV-1 envelope, SIV/HIV (SHIV) chimeras have been developed that facilitate the more reliable testing of antibody-based therapeutics and preventative strategies in nonhuman primates. Building on past findings and developing advanced tools will allow us to continue to leverage rigorous nonhuman primate models for HIV/AIDS as key components in the effort to halt the AIDS pandemic.

Dr. Cynthia Derdeyn
Dr. Donald Sodora
Dr. Jennifer A. Manuzak
Dr. Nina Derby
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • human immunodeficiency virus (HIV)
  • simian immunodeficiency virus (SIV)
  • HIV latency
  • pathogenesis
  • cure
  • vaccination
  • co-infection
  • transmission
  • nonhuman primate models
  • natural hosts
  • infectious diseases

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 3787 KiB  
Article
SIV Infection Is Associated with Transient Acute-Phase Steatosis in Hepatocytes In Vivo
by Nina Derby, Sreya Biswas, Sofiya Yusova, Cristina Luevano-Santos, Maria Cristina Pacheco, Kimberly A. Meyer, Brooke I. Johnson, Miranda Fischer, Katherine A. Fancher, Cole Fisher, Yohannes M. Abraham, Conor J. McMahon, Savannah S. Lutz, Jeremy V. Smedley, Benjamin J. Burwitz and Donald L. Sodora
Viruses 2024, 16(2), 296; https://doi.org/10.3390/v16020296 - 15 Feb 2024
Viewed by 939
Abstract
Metabolic-dysfunction-associated fatty liver disease (MAFLD) is a major cause of morbidity and mortality in HIV-infected individuals, even those receiving optimal antiretroviral therapy. Here, we utilized the SIV rhesus macaque model and advanced laparoscopic techniques for longitudinal collection of liver tissue to elucidate the [...] Read more.
Metabolic-dysfunction-associated fatty liver disease (MAFLD) is a major cause of morbidity and mortality in HIV-infected individuals, even those receiving optimal antiretroviral therapy. Here, we utilized the SIV rhesus macaque model and advanced laparoscopic techniques for longitudinal collection of liver tissue to elucidate the timing of pathologic changes. The livers of both SIV-infected (N = 9) and SIV-naïve uninfected (N = 8) macaques were biopsied and evaluated at four time points (weeks −4, 2, 6, and 16–20 post-infection) and at necropsy (week 32). SIV DNA within the macaques’ livers varied by over 4 logs at necropsy, and liver SIV DNA significantly correlated with SIV RNA in the plasma throughout the study. Acute phase liver pathology (2 weeks post-infection) was characterized by evidence for fat accumulation (microvesicular steatosis), a transient elevation in both AST and cholesterol levels within the serum, and increased hepatic expression of the PPARA gene associated with cholesterol metabolism and beta oxidation. By contrast, the chronic phase of the SIV infection (32 weeks post-infection) was associated with sinusoidal dilatation, while steatosis resolved and concentrations of AST and cholesterol remained similar to those in uninfected macaques. These findings suggest differential liver pathologies associated with the acute and chronic phases of infection and the possibility that therapeutic interventions targeting metabolic function may benefit liver health in people newly diagnosed with HIV. Full article
(This article belongs to the Special Issue Simian Immunodeficiency Virus Models of HIV/AIDS in Nonhuman Primates 2024)
►▼ Show Figures

Figure 1

14 pages, 3076 KiB  
Article
Enhanced IL-17 Producing and Maintained Cytolytic Effector Functions of Gut Mucosal CD161+CD8+ T Cells in SIV-Infected Rhesus Macaques
by Siva Thirugnanam, Edith M. Walker, Faith Schiro, Pyone P. Aye, Jay Rappaport and Namita Rout
Viruses 2023, 15(9), 1944; https://doi.org/10.3390/v15091944 - 18 Sep 2023
Viewed by 1499
Abstract
Previous studies have indicated that the loss of CD161-expressing CD4+ Th17 cells is linked to the progression of chronic HIV. These cells are significantly depleted in peripheral blood and gut mucosa of HIV-infected individuals, contributing to inflammation and disruption of the gut [...] Read more.
Previous studies have indicated that the loss of CD161-expressing CD4+ Th17 cells is linked to the progression of chronic HIV. These cells are significantly depleted in peripheral blood and gut mucosa of HIV-infected individuals, contributing to inflammation and disruption of the gut barrier. However, the impact of HIV infection on CD161-expressing CD8+ T cells remain unclear. Here, we examined the functions of peripheral blood and mucosal CD161+CD8+ T cells in the macaque model of HIV infection. In contrast to the significant loss of CD161+CD4+ T cells, CD161+CD8+ T cell frequencies were maintained in blood and gut during chronic SIV infection. Furthermore, gut CD161+CD8+ T cells displayed greater IL-17 production and maintained Th1-type and cytolytic functions, contrary to impaired IL-17 and granzyme-B production in CD161+CD4+ T cells of SIV-infected macaques. These results suggest that augmented Th17-type effector functions of CD161+CD8+ T cells during SIV infection is a likely mechanism to compensate for the sustained loss of gut mucosal Th17 cells. Targeting the cytokine and cytolytic effector functions of CD161+CD8+ T cells in the preclinical setting of chronic SIV infection with antiretroviral therapy has implications in the restoration of gut barrier disruption in persons with HIV infection. Full article
(This article belongs to the Special Issue Simian Immunodeficiency Virus Models of HIV/AIDS in Nonhuman Primates 2024)
►▼ Show Figures

Figure 1

Review

Jump to: Research

22 pages, 2353 KiB  
Review
Quantitative and Qualitative Distinctions between HIV-1 and SIV Reservoirs: Implications for HIV-1 Cure-Related Studies
by Joseph C. Mudd
Viruses 2024, 16(4), 514; https://doi.org/10.3390/v16040514 - 27 Mar 2024
Viewed by 822
Abstract
The persistence of the latent viral reservoir is the main hurdle to curing HIV-1 infection. SIV infection of non-human primates (NHPs), namely Indian-origin rhesus macaques, is the most relevant and widely used animal model to evaluate therapies that seek to eradicate HIV-1. The [...] Read more.
The persistence of the latent viral reservoir is the main hurdle to curing HIV-1 infection. SIV infection of non-human primates (NHPs), namely Indian-origin rhesus macaques, is the most relevant and widely used animal model to evaluate therapies that seek to eradicate HIV-1. The utility of a model ultimately rests on how accurately it can recapitulate human disease, and while reservoirs in the NHP model behave quantitatively very similar to those of long-term suppressed persons with HIV-1 (PWH) in the most salient aspects, recent studies have uncovered key nuances at the clonotypic level that differentiate the two in qualitative terms. In this review, we will highlight differences relating to proviral intactness, clonotypic structure, and decay rate during ART between HIV-1 and SIV reservoirs and discuss the relevance of these distinctions in the interpretation of HIV-1 cure strategies. While these, to some degree, may reflect a unique biology of the virus or host, distinctions among the proviral landscape in SIV are likely to be shaped significantly by the condensed timeframe of NHP studies. ART is generally initiated earlier in the disease course, and animals are virologically suppressed for shorter periods before receiving interventions. Because these are experimental variables dictated by the investigator, we offer guidance on study design for cure-related studies performed in the NHP model. Finally, we highlight the case of GS-9620 (Vesatolimod), an antiviral TLR7 agonist tested in multiple independent pre-clinical studies in which virological outcomes may have been influenced by study-related variables. Full article
(This article belongs to the Special Issue Simian Immunodeficiency Virus Models of HIV/AIDS in Nonhuman Primates 2024)
►▼ Show Figures

Figure 1

32 pages, 506 KiB  
Review
Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects
by Amitinder Kaur and Monica Vaccari
Viruses 2024, 16(3), 368; https://doi.org/10.3390/v16030368 - 27 Feb 2024
Viewed by 1330
Abstract
The human immunodeficiency virus (HIV) continues to pose a significant global health challenge, with millions of people affected and new cases emerging each year. While various treatment and prevention methods exist, including antiretroviral therapy and non-vaccine approaches, developing an effective vaccine remains the [...] Read more.
The human immunodeficiency virus (HIV) continues to pose a significant global health challenge, with millions of people affected and new cases emerging each year. While various treatment and prevention methods exist, including antiretroviral therapy and non-vaccine approaches, developing an effective vaccine remains the most crucial and cost-effective solution to combating the HIV epidemic. Despite significant advancements in HIV research, the HIV vaccine field has faced numerous challenges, and only one clinical trial has demonstrated a modest level of efficacy. This review delves into the history of HIV vaccines and the current efforts in HIV prevention, emphasizing pre-clinical vaccine development using the non-human primate model (NHP) of HIV infection. NHP models offer valuable insights into potential preventive strategies for combating HIV, and they play a vital role in informing and guiding the development of novel vaccine candidates before they can proceed to human clinical trials. Full article
(This article belongs to the Special Issue Simian Immunodeficiency Virus Models of HIV/AIDS in Nonhuman Primates 2024)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop